A Study to Test Whether Different Doses of BI 1291583 Help People With Bronchiectasis
Status:
Not yet recruiting
Trial end date:
2023-12-29
Target enrollment:
Participant gender:
Summary
This study is open to adults with bronchiectasis. People can join the study if they produce
sputum and have a history of flare-ups (also called exacerbations).
The purpose of this study is to find out whether a medicine called BI 1291583 helps people
with bronchiectasis.
Participants are put into 4 groups randomly, which means by chance. Participants in groups 1,
2, and 3 get different doses of BI 1291583. Participants in group 4 get placebo. Placebo
tablets look like BI 1291583 tablets, but do not contain any medicine. Participants take the
tablets once a day.
Participants are in the study for between 6 months and 1 year. During this time, they visit
the study site about 10 times and get about 5 phone calls from the site staff.
The doctors document when participants experience flare-ups during the study. The time to the
first flare-ups is compared between the treatment groups. Doctors also regularly check
participants' health and take note of any unwanted effects.